

# **PlexPCR<sup>®</sup>** Flu/RSV/SARS-CoV-2

**Upfront Diagnosis**

**Prompt identification of clinically relevant seasonal respiratory viruses**

**Class D  
IVDR  
Certified**




**Improve laboratory productivity during seasonal testing surges**

Adopt Class D IVDR Certified **PlexPCR<sup>®</sup>** Flu/RSV/SARS-CoV-2, to triage and diagnose these important seasonal respiratory viruses upfront.

- ▶ Influenza A
- ▶ Influenza B
- ▶ Respiratory Syncytial Virus (A and B)
- ▶ SARS-CoV-2

# Upfront diagnosis of clinically relevant seasonal respiratory viruses with **PlexPCR**<sup>®</sup> Flu/RSV/SARS-CoV-2

- ▶ Class D IVDR Certified
- ▶ Stay ahead of seasonal influenza that results in substantial worldwide disease burden<sup>1</sup>
- ▶ RSV is an important inclusion. It is a common cause of respiratory infections and the main cause of severe cases of bronchiolitis and pneumonia in infants and young children<sup>2,3</sup>
- ▶ Confidently detect SARS-CoV-2, including current known circulating variants<sup>4</sup>




## Scalable throughput with our flexible workflow. Easily adapt to fluctuating test demand

- ▶ Easily integrate **PlexPCR**<sup>®</sup> Flu/RSV/SARS-CoV-2 into your laboratory by testing on your QuantStudio 5 platform.
- ▶ Enhance your productivity for rapid, routine diagnostics with **PlexPrep**<sup>®</sup> liquid handling automation.
- ▶ Maximise your output with this single-well multiplex test.

## PlexPrep® - clever, compact robotics

Accelerate your sample preparation and qPCR set-up with the **SpeedX PlexPrep®** automation solution. Fast, precise, and easy to use, ideal for testing surges.

- ▶ Includes nimble 8+2 pipetting configuration, liquid level detection, and monitored air displacement technology for rapid and reproducible performance



- ▶ Compact system (63.5cm x 53.4cm, 41.6kg) with integrated touchscreen

- ▶ Compatible with range of primary specimen tubes, extraction consumables, and 96- and 384-well plates



## Affordable and efficient

- ▶ Our smart technology is based on cost-effective components, allowing us to produce affordable assays for you.
- ▶ Utilise your existing QuantStudio 5 instrument and avoid the expense of acquiring new systems and costs associated with training, implementation and service contracts.



**PlexPCR®** Flu/RSV/SARS-CoV-2 is a Class D IVDR certified, single-well multiplex qPCR test detecting clinically relevant seasonal respiratory viruses Influenza A, Influenza B, Respiratory Syncytial Virus (A & B) and SARS-CoV-2 virus, plus an endogenous control<sup>5</sup>.

Powered by proprietary **PlexPCR®** technology demonstrating improved multiplex performance compared with other probe-based tests.<sup>6</sup>

Well	Channel	Target	Clinical evaluation of <b>PlexPCR®</b> Flu/RSV/SARS-CoV-2 <sup>5</sup>			
1	1	Flu A		Flu A	Flu B	RSV
	2	Flu B				SARS-CoV-2
	3	RSV A and RSV B	Sensitivity	100.00%	94.60%	97.20%
	4	SARS-CoV-2 (ORF1ab and RdRp)				99.00%
	5	Endogenous Control	Specificity	99.00%	99.30%	98.90%

Validated with nasopharyngeal swabs.<sup>5</sup>

Adopt **PlexPCR®** Flu/RSV/SARS-CoV-2 to triage and diagnose these important seasonal respiratory viruses upfront.

Product	Compatible	Size	Cat#
<b>PlexPCR®</b> Flu/RSV/SARS-CoV-2	QuantStudio 5	192 reactions†	1703192
Related Products	Compatible	Size	Cat#
<b>PlexPCR®</b> RespiVirus*	LC480 II	100 reactions 192 reactions†	1201001 1201192
<b>PlexPrep®</b> Liquid Handler	Enquire	1 unit	6600200-01

†Additional volumes provided for use with liquid handling systems  
**PlexPCR®** Flu/RSV/SARS-CoV-2 is only available for sale in the E.U.

**References:** 1. Timothy M Uyeki, David S Hui, Maria Zambon, David E Wentworth, Arnold S Monto (August 2022) Influenza, The Lancet, Seminar Volume 400, Issue 10353, P693-706, August 27, 2022 [https://doi.org/10.1016/S0140-6736\(22\)00982-5](https://doi.org/10.1016/S0140-6736(22)00982-5) 2. Borchers AT, Chang C, Gershwin ME, Gershwin LJ (2013) Respiratory syncytial virus—a comprehensive review. Clin Rev Allergy Immunol 45: 331–379. 10.1007/s12016-013-8368-9 3. Jain H, Schweitzer JW, Justice NA. Respiratory Syncytial Virus Infection. [Updated 2023 Jun 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan <https://www.ncbi.nlm.nih.gov/books/NBK459215/> 4. <https://www.who.int/activities/tracking-SARS-CoV-2-variants> 5. **PlexPCR®** Flu/RSV/SARS-CoV-2 Instructions for use 6. Mokany E., Tan Y.L., Bone S.M., Fuery C., Todd A.V., 2013. MNazyme qPCR with superior multiplexing capacity. Clin. Chem. 59(2); 419-426  
**PlexPCR®** Flu/RSV/SARS-CoV-2 and RespiVirus kits are developed and manufactured by **SpeedX** Pty Ltd, Sydney. **PlexPCR®** & **SpeedX®** are registered trademarks of **SpeedX** Pty Ltd. Other copyright and trademarks are the property of the respective owners. **SpeedX** Pty. Ltd. products may be covered by one or more local or foreign patents. Visit [www.plexpcr.com/patents](http://www.plexpcr.com/patents) for comprehensive patent information.

**Australia - SpeedX Pty. Ltd.**

+61 (0)2 9209 4170  
[sales@speedx.com.au](mailto:sales@speedx.com.au)  
Suite 102, 4 Cornwallis Street,  
Eveleigh NSW 2015 Australia

**Europe - SpeedX Ltd.**

+44 (0)330 445 0036  
[sales.uk@speedx.com.au](mailto:sales.uk@speedx.com.au)  
Acre House 11/15 William Road  
London NW1 3ER United Kingdom

Find out more [plexpcr.com](http://plexpcr.com)

